Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05925920 · ClinicalTrials.gov registry record · Phase 1
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
A Phase 1 study of Obesity and Diabetes Mellitus, Type 2, sponsored by Metabolics Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT05925920 is a Phase 1 study of Obesity and Diabetes Mellitus, Type 2 that is active but no longer recruiting, run by Metabolics Pharma. The registered enrollment target is 49 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05925920, a Phase 1 study of Obesity and Diabetes Mellitus, Type 2, is active but no longer recruiting, sponsored by Metabolics Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects and in subjects with obesity and Type 2 diabetes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ENT-03
Study Locations (1)
California
- ProSciento - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2024-12-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05925920
The ClinicalTrials.gov registry entry for NCT05925920 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The listed sponsor is Metabolics Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05925920 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05925920 about?
NCT05925920 is a clinical study titled "Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes". Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects and in subjects with obesity and Type 2 diabetes.
What is the current status of trial NCT05925920?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2023-06-13. Estimated completion is 2024-12-06.
What conditions does trial NCT05925920 study?
This clinical trial studies the following conditions: Obesity, Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT05925920?
The interventions under investigation include: Placebo (DRUG), ENT-03 (DRUG).
Who is sponsoring clinical trial NCT05925920?
This trial is sponsored by Metabolics Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05925920 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.